Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,398.93
+0.8%
+61.82
Arrow-Thin-Down
DJI
49,609.16
+0.0%
+12.19
Arrow-Thin-Down
NASDAQ
26,247.08
+1.7%
+440.88
Arrow-Thin-Down
Bitcoin
$80,614.00
+0.2%
+$190.37
Arrow-Thin-Down
AAPL
$293.41
+2.1%
+$5.97
Arrow-Thin-Down
AMZN
$272.68
+0.6%
+$1.51
Arrow-Thin-Down
GOOG
$396.94
+0.4%
+$1.64
Arrow-Thin-Down
META
$609.53
-1.2%
-$7.28
Arrow-Thin-Down
MSFT
$415.17
-1.3%
-$5.60
Arrow-Thin-Down
NVDA
$215.16
+1.7%
+$3.66
Arrow-Thin-Down
TSLA
$427.99
+3.9%
+$16.20
Most Active StocksDaily Stock GainersDaily Stock Losers

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

By Motley Fool YouTube – Updated Jul 3, 2025 at 1:52PM EST

Explore the exciting world of Neurocrine Biosciences (NBIX +1.78%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 26, 2025.

Read Next

Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Stocks Mentioned

Neurocrine Biosciences Stock Quote
Neurocrine Biosciences
NASDAQ: NBIX
$152.25
(+1.78%)+$2.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services